Journal article

Effectiveness of Switching Smoking-Cessation Medications Following Relapse

Bryan W Heckman, K Michael Cummings, Karin A Kasza, Ron Borland, Jessica L Burris, Geoffrey T Fong, Ann McNeill, Matthew J Carpenter

AMERICAN JOURNAL OF PREVENTIVE MEDICINE | ELSEVIER SCIENCE INC | Published : 2017

Abstract

INTRODUCTION: Nicotine dependence is a chronic disorder often characterized by multiple failed quit attempts (QAs). Yet, little is known about the sequence of methods used across multiple QAs or how this may impact future ability to abstain from smoking. This prospective cohort study examines the effectiveness of switching smoking-cessation medications (SCMs) across multiple QAs. METHODS: Adult smokers (aged ≥18 years) participating in International Tobacco Control surveys in the United Kingdom, U.S., Canada, and Australia (N=795) who: (1) completed two consecutive surveys between 2006 and 2011; (2) initiated a QA at least 1 month before each survey; and (3) provided data for the primary pre..

View full abstract

Grants

Awarded by U.S. National Cancer Institute


Awarded by Canadian Institutes of Health Research


Awarded by National Health and Medical Research Council of Australia


Awarded by Cancer Research United Kingdom


Awarded by Robert Wood Johnson Foundation


Awarded by Canadian Tobacco Control Research Initiative



Awarded by NATIONAL CANCER INSTITUTE


Awarded by NATIONAL INSTITUTE ON DRUG ABUSE


Funding Acknowledgements

The research presented in this paper is that of the authors and does not reflect the official policy of the funders. Major funders of the International Tobacco Control Four Country Survey: U.S. National Cancer Institute (P50 CA111326, P01 CA138389, R01 CA100362, R01 CA125116), Canadian Institutes of Health Research (57897, 79551, and 115016), National Health and Medical Research Council of Australia (265903, 450110, and 1005922), Cancer Research United Kingdom (C312/A3726, C312/A6465, and C312/A11039), Robert Wood Johnson Foundation (045734), and Canadian Tobacco Control Research Initiative (014578), with additional support from the Propel Centre for Population Health Impact, the Ontario Institute for Cancer Research, and the Canadian Cancer Society Research Institute. BWH was supported by K12 DA031794 and K23 DA041616. JLB was supported by K07 CA181351. None of the sponsors played any direct role in the design or conduct of the study; the collection, management, analysis or interpretation of the data; in the preparation of the manuscript, or in the decision to submit the manuscript for publication.KMC has received grant funding from Pfizer, Inc., to study the impact of a hospital-based tobacco-cessation intervention, and has received funding as an expert witness in litigation filed against the tobacco industry. No other financial disclosures were reported by the authors of this paper.